A Novel Bispecific LILRB4 x CD3 Antibody with Potent killing of Monocytic Acute Myeloid Leukemia Cells

Written By Vikki Christian

Huang, T., et al.  The American Association for Cancer Research (AACR) Annual Meeting 2023. April 14–19, 2023

Vikki Christian
Previous

A first-in-human phase 1 study of IO-202 (anti-LILRB4 mAb) in acute myeloid leukemia (AML) with monocytic differentiation and chronic myelomonocytic leukemia (CMML) patients
Next

First-In-Human Phase 1 Trial of IO-108, an Antagonist Antibody Targeting LILRB2 (ILT4) as Monotherapy and in Combination with Pembrolizumab in Advanced Solid Tumors: Dose Escalation Data